80 citations
,
January 1995 in “The Nephron journals/Nephron journals” The treatment was effective for lupus nephritis with manageable side effects.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
7 citations
,
February 2023 in “Exploration of Medicine” Drug repurposing offers promising strategies to improve tuberculosis treatment despite challenges.
29 citations
,
July 2012 in “Fertility and Sterility” Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.
5 citations
,
January 2024 in “Crystals” The salts have diverse molecular packing with significant hydrogen interactions.
4 citations
,
August 2021 in “Annals of Translational Medicine” Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
1 citations
,
January 2012 in “Ancient Science of Life” Eclipta alba extract reduces ulcers and protects the stomach in rats.
9 citations
,
November 2017 in “International Journal of Nanomedicine” Tiny particles called anionic squarticles can effectively remove a common antidepressant from the body after an overdose.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
January 1994 in “Toxicological Sciences” Lower dosages of 2-(difluoromethyl)-dl-ornithine might reduce side effects, supporting further research.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
1 citations
,
November 2000 in “PubMed” Combining cytostatic and steroid drugs effectively treats systemic lupus erythematosus.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
12 citations
,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
1 citations
,
February 1994 in “Drug Investigation” Sulfasalazine might cause hair loss, especially in women, and stopping it can reverse the hair loss.
75 citations
,
June 2007 in “Journal of Biological Chemistry” MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.
13 citations
,
April 2013 in “Immunotherapy” Inhibiting PLA2 enzymes may help treat inflammatory skin diseases like psoriasis and dermatitis.
48 citations
,
July 1996 in “Human & Experimental Toxicology” Human enzymes can detoxify harmful substances but might also increase their cancer risk.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
March 2024 in “Organic letters” A new method efficiently modifies alkenes to create useful medicinal compounds.